2011 News Releases

iCo Therapeutics Inc. Engages Ora for Ophthalmic Clinical & Regulatory Guidance

 For Immediate Release                                                                                  May 13, 2011

VANCOUVER, Canada - iCo Therapeutics Inc. (TSX-V: ICO) announced today that it has entered into a consulting agreement with Ora Inc., ("Ora"), a global leader in ophthalmic product development. Ora's scope of services relate to iCo-007 Phase 2 clinical development.

"We are pleased to be able to access Ora's extensive ophthalmic development expertise and professional networks as we continue to advance our Phase 2 program in Diabetic Macular Edema", stated Andrew Rae, iCo's President & CEO.

"Ora is excited to collaborate with iCo on the development of their antisense inhibitor targeting C-raf kinase messenger ribonucleic acid (mRNA) which represents a novel mechanism of action for treating sight threatening ophthalmic diseases", stated Stuart Abelson, Ora's President & CEO.

About Ora

Ora is the world's leading independent ophthalmic product development firm, with more than 30 product approvals during its 30-year history. Ora helps clients garner NDA approvals by providing strategic clinical-regulatory guidance and complete turnkey clinical trial conduct and management. Ora's technology-based, concept-to-market services and solutions accelerate development timelines and improve the scientific quality of clinical research along every step of the development pathway. For more information, visit the Ora website at: www.oraclinical.com.

About iCo-007

Designed and discovered by ISIS Pharmaceuticals Inc., (NASDAQ: ISIS), iCo-007 is a second-generation antisense drug targeting c-Raf kinase for the treatment of DME and diabetic retinopathy.  iCo-007 completed an open label, dose escalating Phase 1 trial with safety as the primary endpoint, and visual acuity and measures of retinal thickness serving as secondary endpoints.  Importantly, iCo saw no drug-related serious adverse events, no signs of ocular inflammation, no intraocular pressure issues and no systemic exposure.  Encouraging trends in measured secondary endpoints warrant further investigation. Four U.S. clinical sites participated in the trial.

About iCo Therapeutics

iCo Therapeutics Inc. is a Vancouver-based reprofiling company focused on redosing or reformulating drugs with clinical history for new or expanded indications.   iCo has exclusive worldwide rights to three products: iCo-007, moving into Phase 2 for the treatment of DME, iCo-008; a product with Phase 2 clinical history to be developed for severe ocular allergies and age-related macular degeneration; and iCo-009, an oral formulation of Amphotericin B for sight and life-threatening diseases. iCo granted a license option for iCo-008 systemic uses to Immune Pharmaceuticals in December 2010. iCo-009 also represents a new drug delivery technology with the potential to reprofile other parenteral administered drugs to the oral route of administration.   iCo was recently awarded a Gold Leaf Award as the Early Stage Company of the Year from BIOTECanada and is a Canada's Top 10™ Competition winner.  iCo trades on the TSX Venture Exchange under the symbol "ICO".  For more information, visit the Company website at: www.icotherapeutics.com

No regulatory authority has approved or disapproved the content of this release.  The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Forward Looking Statements

Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on iCo Therapeutics' current beliefs as well as assumptions made by and information currently available to iCo Therapeutics and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release.  Due to risks and uncertainties, including the risks and uncertainties identified by iCo Therapeutics in its public securities filings; actual events may differ materially from current expectations. iCo Therapeutics disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

Copyright 2015 ICO Therapeutics | Disclaimer